Market Cap 403.50M
Revenue (ttm) 0.00
Net Income (ttm) -15.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 293,200
Avg Vol 266,820
Day's Range N/A - N/A
Shares Out 6.68M
Stochastic %K 43%
Beta 1.46
Analysts Strong Sell
Price Target $112.21

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imagi...

Industry: Biotechnology
Sector: Healthcare
Phone: 847 388 0349
Address:
1000 Skokie Boulevard, Suite 350, Wilmette, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 30 at 3:27 AM
$MNPR RSI: 59.31, MACD: -0.4148 Vol: 3.70, MA20: 67.52, MA50: 73.16 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 21 at 4:18 PM
$MNPR Fingers crossed here
0 · Reply
Quantumup
Quantumup Jan. 21 at 12:13 PM
Cantor reiterated $MNPR Overweight/$109 $AZN Cantor said in its note: Monopar tells us they met with the FDA last year and that the company remains on track to file an NDA in 1H26. Recall, there is also a Patient-Focused Drug Development (PFDD) Meeting taking place next week, 1/29. This is the core priority for the company this year. If you've ever met CEO Dr. Chandler Robinson, then you'll know there is nothing more important to him than getting this therapy to patients. While he understands that investors are curious to hear the specifics behind these meetings, it's very important for him to maintain the high integrity of the review process. Thus, we didn't hear any color. But our own take is that things must be progressing well considering filing plans remain on track.
0 · Reply
Arcides
Arcides Jan. 13 at 2:17 AM
$MNPR looks like a good time to buy monopar
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 11 at 9:38 PM
$RADX strains more ownership in Radiopharm Ventures now at 87.5% yielding a basket of new therapeutics. B7-H3 created with the collaboration is now Phase 1 approved. Radiopharm Ventures = MD Anderson + Radiopharm Theranostics. Trading at 5-6% value of $AKTS with a more advanced diversified pipeline. $IMNM $MNPR
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 5 at 12:35 PM
$MNPR RSI: 27.35, MACD: -3.8831 Vol: 5.07, MA20: 71.67, MA50: 78.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
UgoGreg
UgoGreg Jan. 1 at 11:07 PM
$MNPR https://youtu.be/ygBN8MilTyc
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 30 at 2:42 PM
$30 target for Radiopharm Theranostics. Rad101 reached 92% on potentially 3rd largest radiopharm imaging brain mets phase 2b. Lantheus owns 14.5% $RADX $CATX $MNPR $PYXS
1 · Reply
TheVariableV
TheVariableV Dec. 25 at 9:49 AM
$MNPR Upside depends on translating ambition into measurable cadence, with macro volatility magnifying operational missteps. The upside case requires evidence, not projection.
0 · Reply
trading_momentum_x
trading_momentum_x Dec. 23 at 3:09 AM
$MNPR has reversed sharply off the 64–65 demand zone, forming a clear sequence of higher lows and pushing back toward equilibrium. The bounce is impulsive relative to the prior decline, suggesting active dip-buying rather than a passive drift. Price is now testing the 72–73 equilibrium / mid-range area, where short-term pauses are likely. The larger overhead 79–80 supply zone remains the key upside cap and will likely attract sellers on any continuation. Key levels: Resistance: 72–73 initially, then 79–80 Support: 68–69, followed by 65–64 if momentum fades Bottom line: MNPR is in a strong short-term recovery off demand, but it is now entering a decision area. Acceptance above the low-70s would keep the rebound intact; failure would shift the move back into corrective territory.
0 · Reply
Latest News on MNPR
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025, 2:30 AM EDT - 9 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025


Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule


Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split


Monopar and NorthStar Amend & Extend Collaboration

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Monopar and NorthStar Amend & Extend Collaboration


Monopar Announces CFO Succession

May 24, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces CFO Succession


OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 30 at 3:27 AM
$MNPR RSI: 59.31, MACD: -0.4148 Vol: 3.70, MA20: 67.52, MA50: 73.16 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 21 at 4:18 PM
$MNPR Fingers crossed here
0 · Reply
Quantumup
Quantumup Jan. 21 at 12:13 PM
Cantor reiterated $MNPR Overweight/$109 $AZN Cantor said in its note: Monopar tells us they met with the FDA last year and that the company remains on track to file an NDA in 1H26. Recall, there is also a Patient-Focused Drug Development (PFDD) Meeting taking place next week, 1/29. This is the core priority for the company this year. If you've ever met CEO Dr. Chandler Robinson, then you'll know there is nothing more important to him than getting this therapy to patients. While he understands that investors are curious to hear the specifics behind these meetings, it's very important for him to maintain the high integrity of the review process. Thus, we didn't hear any color. But our own take is that things must be progressing well considering filing plans remain on track.
0 · Reply
Arcides
Arcides Jan. 13 at 2:17 AM
$MNPR looks like a good time to buy monopar
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 11 at 9:38 PM
$RADX strains more ownership in Radiopharm Ventures now at 87.5% yielding a basket of new therapeutics. B7-H3 created with the collaboration is now Phase 1 approved. Radiopharm Ventures = MD Anderson + Radiopharm Theranostics. Trading at 5-6% value of $AKTS with a more advanced diversified pipeline. $IMNM $MNPR
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 5 at 12:35 PM
$MNPR RSI: 27.35, MACD: -3.8831 Vol: 5.07, MA20: 71.67, MA50: 78.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
UgoGreg
UgoGreg Jan. 1 at 11:07 PM
$MNPR https://youtu.be/ygBN8MilTyc
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 30 at 2:42 PM
$30 target for Radiopharm Theranostics. Rad101 reached 92% on potentially 3rd largest radiopharm imaging brain mets phase 2b. Lantheus owns 14.5% $RADX $CATX $MNPR $PYXS
1 · Reply
TheVariableV
TheVariableV Dec. 25 at 9:49 AM
$MNPR Upside depends on translating ambition into measurable cadence, with macro volatility magnifying operational missteps. The upside case requires evidence, not projection.
0 · Reply
trading_momentum_x
trading_momentum_x Dec. 23 at 3:09 AM
$MNPR has reversed sharply off the 64–65 demand zone, forming a clear sequence of higher lows and pushing back toward equilibrium. The bounce is impulsive relative to the prior decline, suggesting active dip-buying rather than a passive drift. Price is now testing the 72–73 equilibrium / mid-range area, where short-term pauses are likely. The larger overhead 79–80 supply zone remains the key upside cap and will likely attract sellers on any continuation. Key levels: Resistance: 72–73 initially, then 79–80 Support: 68–69, followed by 65–64 if momentum fades Bottom line: MNPR is in a strong short-term recovery off demand, but it is now entering a decision area. Acceptance above the low-70s would keep the rebound intact; failure would shift the move back into corrective territory.
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 3:18 PM
Biotech boom in 2025: Can $IONS, $GPCR, $MNPR, and $KOD keep the momentum? IONS soared 120.5% with strong pipeline progress and favorable regulatory developments. GPCR up 127.2% on promising obesity drug data. MNPR skyrocketed 185.9% fueled by positive investor expectations regarding its lead candidate. KOD surged 181.1% on solid late-stage pipeline potential. See the full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-body-25804&ADID=SYND_STOCKTWITS_TWEET_2_2807434_BODY_25804
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 2:18 PM
These biotech names more than doubled in 2025 — momentum or mania? $IONS, $GPCR, $MNPR, and $KOD all surged over 100% in 2025, fueled by policy clarity, a revival in M&A activity, and key clinical wins pushing biotech momentum into 2026. Which of these winners still has room to run — and which could fade? Full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-teaser-25785&ADID=SYND_STOCKTWITS_TWEET_2_2807434_TEASER_25785
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 20 at 8:34 PM
How Radioisotopes Are Being Used to De-Risk Antibody-Drug Conjugate (ADC) Development $RADX $IMNM $MNPR $PYXS https://blog.championsoncology.com/blog/how-radiopharmaceuticals-are-being-used-to-de-risk-antibody-drug-conjugate-adc-development
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 20 at 7:31 PM
$MNPR RADX on Monday now at $5.19 do your DD
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 3:13 AM
0 · Reply
ssdsddssd2
ssdsddssd2 Dec. 7 at 2:30 PM
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 2 at 1:45 AM
$RADX Radiopharm Theranostics $30 target at Jones Trading $NNE $ASPI $MNPR
3 · Reply
RadioIsotope25
RadioIsotope25 Nov. 25 at 3:44 PM
Therapeutic Radiopharmaceuticals: Download 2025 Global Report - Clinical Trials Arena $RADX $CBSR $CATX $MNPR https://www.clinicaltrialsarena.com/sponsored/therapeutic-radiopharmaceuticals-download-2025-global-report/
0 · Reply
ScreenerIQ
ScreenerIQ Nov. 23 at 5:49 PM
Some Stocks showing strong relative strength. Filtered on '5-Day Return'. Please DYOResearch. Some examples: $EYPT $MNPR $NTRA $DY #StockMarket #investing #Trading
0 · Reply
Stanfordfund
Stanfordfund Nov. 22 at 1:20 PM
$MNPR Never sell!
0 · Reply
milanmoses
milanmoses Nov. 19 at 5:14 PM
Big eyes on $MNPR: their Wilson disease candidate + radiopharma combo is rare.
0 · Reply